Merck (NYSE:MRK) announced a major reorganization of its Human Health business into two global units focused on Oncology and on Specialty, Pharma & Infectious Diseases. The company named new senior ...
Gilead Sciences (GILD) announced on Thursday that its Phase 3 ARTISTRY-1 trial, which tested its new single-tablet regimen of bictegravir and lenacapavir in adults with HIV, reached the primary ...
Add Yahoo as a preferred source to see more of our stories on Google. Logos of Gilead at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, ...
Gilead Sciences Inc. (NASDAQ: GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of HIV patients who are virologically ...
In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the first once-daily single tablet HIV ...
Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, was found to be non-inferior to Gilead’s (GILD) once-daily HIV pill Biktarvy ...
The biopharmaceutical company said Monday that the treatment, a once-daily single tablet of bictegravir and lenacapavir, was found to be statistically non-inferior to an existing treatment, Biktarvy.
Logos of Gilead at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov Dec 15 (Reuters) - Gilead Sciences said on Monday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results